Dr. Hensing on the Management of Stage III NSCLC

Thomas A. Hensing, MD
Published: Tuesday, Oct 03, 2017



Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses the management of patients with stage III non–small cell lung cancer (NSCLC).

Hensing says that in order to avoid the one-size-fits-all approach that has plagued stage IV disease management, new technology and novel therapeutics need to be adopted.

One of these technologies is proton-beam radiotherapy, but the problem is that it is expensive and there is limited access for patients, says Hensing.
 


Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses the management of patients with stage III non–small cell lung cancer (NSCLC).

Hensing says that in order to avoid the one-size-fits-all approach that has plagued stage IV disease management, new technology and novel therapeutics need to be adopted.

One of these technologies is proton-beam radiotherapy, but the problem is that it is expensive and there is limited access for patients, says Hensing.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x